Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in China

Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in China

Introduction: Linaclotide, a guanylate cyclase C agonist that improves the symptoms of irritable bowel syndrome with predominant constipation (IBS-C), has been recently approved for IBS-C treatment. This study aimed to report real-world data on linaclotide treatment in China. Methods: This was a pro...

Full description

Bibliographic Details
Main Authors: Gou, X.B (Author), Guo, J. (Author), Guo, S. (Author), Li, B. (Author), Li, Q. (Author), Liu, L. (Author), Lv, X. (Author), Wang, H. (Author), Wang, Y. (Author), Xu, E. (Author), Zhang, W. (Author), Zhao, W. (Author), Zhu, Q. (Author)
Format: Article
Language:English
Published: SAGE Publications Ltd 2022
Subjects:
abdominal pain
adverse events
Bowel movements
IBS-C
linaclotide
Online Access:View Fulltext in Publisher

Similar Items

Similar Items